1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Switzerland >
  5. GSK Acquires Okairos AG

M&A Deal Summary

GSK Acquires Okairos AG

On May 29, 2013, GSK acquired life science company Okairos AG for 250M EUR

Acquisition Highlights
  • This is GSK’s 19th transaction in the Life Science sector.
  • This is GSK’s 18th largest (disclosed) transaction.
  • This is GSK’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2013-05-29
Target Okairos AG
Sector Life Science
Buyer(s) GSK
Deal Type Add-on Acquisition
Deal Value 250M EUR

Target

Okairos AG

Basel, Switzerland
Okairos - is a non-listed clinical-stage biopharmaceutical company, developing genetic vaccines for major infectious diseases - including malaria, hepatitis C, HIV, respiratory syncytial virus and cancer - using a novel proprietary technology. The company is also pursuing therapeutic vaccines to treat cancer.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

GSK

Brentford, United Kingdom
Category Company
Founded 1715
Sector Life Science
Employees68,629
Revenue 31.4B GBP (2024)
DESCRIPTION
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.

GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.

DEAL STATS #
Overall 23 of 35
Sector: Life Science M&A 19 of 28
Type: Add-on Acquisition M&A Deals 17 of 25
Country: Switzerland M&A 1 of 2
Year: 2013 M&A 1 of 1
Size (of disclosed) 18 of 31
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-08-15 GlaxoSmithKline - 25 Pharmaceutical Products

Australia

GlaxoSmithKline - 25 Pharmaceutical Products comprise long established pharmaceutical brands of proven performance. The main areas of therapeutic treatment of the Products are analgesic, antibiotics, anti-virals and the central nervous system. Other areas covered include anti-nauseant, anti-inflammatory and muscle relaxants. The leading Products are well recognised brands including Amoxil, Augmentin, Imigran, Kapanol, Lamactil, Mesasal, Timentin, Valtrex, Zantac and Zofran.

Sell £172M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-09-09 Lucozade Ribena Suntory

Uxbridge, United Kingdom

Lucozade Ribena Suntory is a brand new company, home to two of the UK’s biggest soft drinks brands, and is the third largest branded soft drinks supplier in the UK market. Ribena is the #1 Juice drinks brand and Lucozade is the #1 selling Sports Drink in the UK.

Sell £1.4B
Mergr

Solution for

Product

Company

Legal